Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belapectin + Pembrolizumab in Advanced Melanoma, NSCLC, and HNSCC
NCT02575404Phase 1Completed
- Start
- May 2016
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of belapectin in melanoma, non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) (4 arms). Primary endpoint: Frequency and Severity of Treatment-Related Adverse Events at 85 days. Started May 2016; status: completed.
02
Drugs
belapectin
03
Conditions
melanomanon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02575404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02575404.